AI for drug discovery:
Intellomx identifies and develops optimal drug targets across multiple indications, both in-house and as a fee-for-service.
Intellomx has developed the next generation of AI/ML for drug discovery, using “Swarm-Based Neural Networks” which enables optimised parallel computing to reveal the hidden biology of disease. This IP-protected in silico approach eliminates many years and millions of dollars of wet lab research to reveal, with high precision, novel drug targets for development of new therapeutic paradigms.

Intellomx is new to BC in 2024. Our HQ is in Nottingham, England and we have a wholly-owned subsidiary in Wuhan, China.

Intellomx is working with some of the worlds largest pharma companies and most advanced biotechnology businesses to develop our novel therapeutics. We also undertake fee-for-service projects for select partners primarily in order to optimise target identification or target validation.

2nd Generation AI:
Large Language Models, image analysis and automation of research protocols represents Generation#1 when it comes to AI for drug discovery.
These systems are useful, accelerating R&D and capturing prior knowledge but are prone to false discovery, have a high compute cost and are reliant on and thus severely constrained by knowledge of known biology. As a result, the output from Generation #1 has been disappointing and, in many cases, has failed to deliver its promise.

Generation #2 augments knowledge via de novo research at the molecular level. It is evidenced-based - based on mathematics not language/LLM. It analyses current clinical data and has minimal reliance on data quality by employing a swarm-based approach. It optimises target selection via multi-parameter ranking. It generates easily-interpreted output that confirms the known biology of disease pathways whilst at the same time revealing what was previously unknown, allowing us to identify the drivers of disease. Intellomx is thus focused on causality.

It is trite but true: Generation #1 reads the literature. Generation #2 writes the literature.